Wedbush Securities Inc. Raises Position in Pfizer Inc. (NYSE:PFE)

Wedbush Securities Inc. grew its stake in Pfizer Inc. (NYSE:PFE) by 2.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 202,238 shares of the biopharmaceutical company’s stock after purchasing an additional 5,697 shares during the quarter. Wedbush Securities Inc.’s holdings in Pfizer were worth $5,365,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of the stock. Retirement Wealth Solutions LLC bought a new position in shares of Pfizer during the fourth quarter valued at about $26,000. Rialto Wealth Management LLC bought a new position in shares of Pfizer during the 4th quarter worth approximately $26,000. Kohmann Bosshard Financial Services LLC purchased a new position in shares of Pfizer in the 4th quarter worth approximately $28,000. Noble Wealth Management PBC bought a new position in shares of Pfizer in the fourth quarter valued at approximately $31,000. Finally, Curio Wealth LLC purchased a new stake in shares of Pfizer during the fourth quarter valued at approximately $32,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

NYSE:PFE opened at $22.99 on Friday. The company has a market capitalization of $130.39 billion, a price-to-earnings ratio of 16.31, a PEG ratio of 0.64 and a beta of 0.61. The business has a 50 day moving average of $25.87 and a 200 day moving average of $26.76. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. Pfizer Inc. has a 1-year low of $22.95 and a 1-year high of $31.54.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. During the same period last year, the company earned $0.10 EPS. Pfizer’s revenue for the quarter was up 24.7% compared to the same quarter last year. On average, sell-side analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Ronald E. Blaylock acquired 19,457 shares of the business’s stock in a transaction on Thursday, February 13th. The shares were acquired at an average cost of $25.65 per share, with a total value of $499,072.05. Following the transaction, the director now owns 27,707 shares in the company, valued at $710,684.55. The trade was a 235.84 % increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 0.06% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have weighed in on PFE. Citigroup reissued a “neutral” rating on shares of Pfizer in a research report on Thursday, March 27th. Truist Financial cut their price target on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a report on Wednesday, December 18th. Hsbc Global Res upgraded shares of Pfizer to a “strong-buy” rating in a report on Monday, March 10th. Guggenheim reiterated a “buy” rating on shares of Pfizer in a research note on Tuesday, March 18th. Finally, Bank of America restated a “neutral” rating and set a $29.00 price target on shares of Pfizer in a research note on Tuesday, December 10th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating, six have issued a buy rating and three have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $31.92.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.